Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $444.70, for a total transaction of $1,778,800.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $57,811. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $440.00 on Friday. The company’s 50-day moving average is $372.27 and its 200 day moving average is $323.67. The company has a market capitalization of $19.85 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 6.71 and a beta of 0.66. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $5.85 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics during the second quarter valued at about $29,000. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the period. SVB Wealth LLC bought a new stake in shares of United Therapeutics during the first quarter valued at about $32,000. Finally, Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on UTHR shares. Morgan Stanley boosted their price target on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a report on Friday. UBS Group boosted their price objective on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Oppenheimer boosted their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Finally, Jefferies Financial Group boosted their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $457.21.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.